LXRX Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
11.3M
+1525.7%
692.0K
-96.7%
21.1M
+295.4%
5.3M
-62.4%
14.2M
Cost of Revenue
79.0K
+102.6%
39.0K
-63.9%
108.0K
-46.3%
201.0K
+1910.0%
10.0K
Gross Profit
11.2M
+1610.7%
653.0K
-96.9%
21.0M
+308.8%
5.1M
-63.8%
14.2M
Operating Expenses
25.7M
-5.6%
27.2M
+15.3%
23.6M
+17.5%
20.1M
-23.9%
26.4M
R&D
16.2M
-7.1%
17.4M
+36.7%
12.8M
+12.7%
11.3M
-39.7%
18.8M
SG&A
9.5M
-3.0%
9.8M
+5.6%
9.2M
+5.4%
8.8M
+15.2%
7.6M
Operating Income
-14495000
+45.4%
-26540000
-926.3%
-2586000
+82.7%
-14936000
-22.6%
-12187000
EBITDA
-14400000
+45.5%
-26438000
-967.8%
-2476000
+83.3%
-14818000
-23.1%
-12036000
Net Income
-14005000
+55.9%
-31775000
-2946.5%
-1043000
+93.3%
-15530000
-21.6%
-12769000
EPS (Basic)
$-0.03
+57.1%
$-0.07
$0.00
+100.0%
$-0.04
+0.0%
$-0.04
EPS (Diluted)
$-0.03
+57.1%
$-0.07
$0.00
+100.0%
$-0.04
+0.0%
$-0.04
Shares (Diluted)
445.0M
+1.7%
437.7M
+9.3%
400.2M
+10.2%
363.2M
-0.1%
363.4M
Lexicon Pharmaceuticals (LXRX) — Financials